University Hospital, Tours
Small vessel disease (SVD) accounts for 25% of strokes and is the second most common cause of dementia after Alzheimer's disease. Unlike other causes of stroke, SVD manifests itself years before the stroke by the accumulation of tissue damage. Although heterogeneous, these lesions appear on Magnetic Resonance Imaging (MRI) as white matter hypersignals (WMH). In this context, the ANR SUMMIT project will characterize these lesions in vivo to develop new markers in the early stages of stroke. It is subdivided into 4 work packages, the third one being promoted by CHRU de Tours.
Small Vessel Disease
MRI
NA
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 20 participants |
| Masking : | NONE |
| Primary Purpose : | DIAGNOSTIC |
| Official Title : | Small Vessel Diseases: Ultra-realistic Microstructure Computational Model to Refine Individual Treatment |
| Actual Study Start Date : | 2024-03-26 |
| Estimated Primary Completion Date : | 2026-03 |
| Estimated Study Completion Date : | 2026-03 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 82 Years to 100 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
UHT of Tours
Tours, France,